1 week Ago By Defense World Staff
iCAD, Inc. ( NASDAQ:ICAD – Get Free Report )’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.
59 and traded as high as $1.97. iCAD shares last traded at $1.
83, with a volume of 138,448 shares. Wall Street Analyst Weigh In Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a research report on Thursday, November 21st.
View Our Latest Analysis on ICAD iCAD Stock Performance Institutional Investors Weigh In On iCAD An institutional investor recently bought a new position in iCAD stock. Essex LLC bought a new stake in iCAD, Inc. ( NASDAQ:ICAD – Free Report ) during the third quarter, according to the company in its most recent disclosure with the SEC.
The firm bought 137,963 shares of the technology company’s stock, valued at approximately $216,000. Essex LLC owned approximately 0.52% of iCAD as of its most recent filing with the SEC.
24.61% of the stock is currently owned by institutional investors and hedge funds. iCAD Company Profile ( Get Free Report ) iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States.
It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. Featured Stories Five stocks we like better than iCAD How to Invest in Small Cap Stocks Work and Play: Investing in the Rise of Bleisure Travel Stock Sentiment Analysis: How it Works Top Dividend Stocks to Buy Now as Bond Yields Could Lower How to Invest in the FAANG Stocks SAP: AI Tailwinds Accelerating Enterprise Cloud Business Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.
com's FREE daily email newsletter ..
